Publicaciones en colaboración con investigadores/as de University of Toronto (17)

2022

  1. Engineering pan-HIV-1 neutralization potency through multispecific antibody avidity

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 119, Núm. 4

2021

  1. Focal accumulation of aromaticity at the CDRH3 loop mitigates 4E10 polyreactivity without altering its HIV neutralization profile

    iScience, Vol. 24, Núm. 9

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. Affinity for the Interface Underpins Potency of Antibodies Operating In Membrane Environments

    Cell Reports, Vol. 32, Núm. 7

2019

  1. Molecular recognition of the native HIV-1 MPER revealed by STED microscopy of single virions

    Nature Communications, Vol. 10, Núm. 1

2018

  1. Functional variants in the LRRK2 gene confer shared effects on risk for Crohn's disease and Parkinson's disease

    Science Translational Medicine, Vol. 10, Núm. 423

2017

  1. Diverse Applications of Nanomedicine

    ACS Nano, Vol. 11, Núm. 3, pp. 2313-2381

2016

  1. Specific cytoarchitectureal changes in hippocampal subareas in daDREAM mice

    Molecular Brain, Vol. 9, Núm. 1

2015

  1. Phosphorylation-dependent changes in nucleotide binding, conformation, and dynamics of the first nucleotide binding domain (NBD1) of the sulfonylurea receptor 2B (SUR2B)

    Journal of Biological Chemistry, Vol. 290, Núm. 37, pp. 22699-22714

2014

  1. DREAM controls the on/off switch of specific activity-dependent transcription pathways

    Molecular and Cellular Biology, Vol. 34, Núm. 5, pp. 877-887

  2. Structure and immunogenicity of a peptide vaccine, including the complete HIV-1 gp41 2F5 epitope: Implications for antibody recognition mechanism and immunogen design

    Journal of Biological Chemistry, Vol. 289, Núm. 10, pp. 6565-6580

2012

  1. NMR and fluorescence studies of drug binding to the first nucleotide binding domain of SUR2A

    Biochemistry, Vol. 51, Núm. 45, pp. 9211-9222

2011

  1. Interaction of anti-HIV type 1 antibody 2F5 with phospholipid bilayers and its relevance for the mechanism of virus neutralization

    AIDS Research and Human Retroviruses, Vol. 27, Núm. 8, pp. 863-876

2010

  1. Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding

    Journal of Virology, Vol. 84, Núm. 9, pp. 4136-4147

  2. Putative one-pot prebiotic polypeptides with ribonucleolytic activity

    Chemistry - A European Journal, Vol. 16, Núm. 18, pp. 5314-5323

2009

  1. Structural Constraints Imposed by the Conserved Fusion Peptide on the HIV-1 gp41 Epitope Recognized by the Broadly Neutralizing Antibody 2F5

    Journal of Physical Chemistry B, Vol. 113, Núm. 41, pp. 13626-13637

2008

  1. Structural Details of HIV-1 Recognition by the Broadly Neutralizing Monoclonal Antibody 2F5: Epitope Conformation, Antigen-Recognition Loop Mobility, and Anion-Binding Site

    Journal of Molecular Biology, Vol. 384, Núm. 2, pp. 377-392